Theralase Technologies (CVE:TLT) Stock Price Down 15.8% - Should You Sell?

Theralase Technologies Inc. (CVE:TLT - Get Free Report) shares fell 15.8% during trading on Tuesday . The company traded as low as C$0.32 and last traded at C$0.32. 116,882 shares changed hands during trading, an increase of 1% from the average session volume of 115,945 shares. The stock had previously closed at C$0.38.

Theralase Technologies Trading Down 3.9 %

The stock has a 50-day simple moving average of C$0.18 and a 200 day simple moving average of C$0.18. The company has a market cap of C$89.62 million, a price-to-earnings ratio of -15.00 and a beta of 1.36. The company has a current ratio of 1.21, a quick ratio of 3.40 and a debt-to-equity ratio of 20.58.

Theralase Technologies (CVE:TLT - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported C($0.01) earnings per share for the quarter. The business had revenue of C$0.10 million during the quarter. As a group, equities research analysts predict that Theralase Technologies Inc. will post -0.05 EPS for the current fiscal year.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.